<DOC>
	<DOCNO>NCT00304538</DOCNO>
	<brief_summary>The purpose study identify safe dose low dose glucagon prevent hypoglycemia patient Type I diabetes use insulin pump measure amount glucagon blood see body respond glucagon .</brief_summary>
	<brief_title>A Study Safety , Tolerability , Pharmacokinetics Pharmacodynamic Activity Very Low Dose-Glucagon Subjects With Type 1 Diabetes Mellitus</brief_title>
	<detailed_description>Glucagon currently use treat severe hypoglycemia . DiObex believe glucagon replacement therapy low dos glucagon may prevent hypoglycemia without compromise effective glycemic control insulin . In study low dos glucagon administer Type I diabetics use insulin pump . The glucagon administer subcutaneously overnight 6 , 9 12 hour see number mild impend hypoglycemia event safely decrease . Three different dos glucagon compare control infusion .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 1</mesh_term>
	<mesh_term>Glucagon</mesh_term>
	<mesh_term>Glucagon-Like Peptide 1</mesh_term>
	<criteria>1 . Males female , 18 55 year age , require daily insulin management type 1 diabetes mellitus &gt; 10 year 2 . On stable basal insulin regimen use CSII therapy ( “ stable ” define total daily dose insulin change ± 20 % 2 month prior screen ) 3 . Glycosylated hemoglobin ( HbA1c ) ≤8.0 % 4 . Total daily insulin requirement ≤1 unit/kg body weight 5 . Fasting Cpeptide level &lt; 1.0 ng/mL ( &lt; 330 pmol/L ) ( may do screening may take subject ’ medical record perform within past 12 month ) 6 . Body mass index ( BMI ) ≤25.5 kg/m2 body weight past 6 month within ± 5 % 7 . Hemoglobin , hematocrit , platelet within normal limit ; clinically significant abnormality white blood cell ( WBC ) differential 8 . Serum chemistry result within normal limit except liver enzyme [ aspartate transaminase ( AST ) alanine transaminase ( ALT ) ] must within 2.5 time upper limit normal ( ULN ) creatinine must &lt; 1.6 mg/dL 9 . Normal thyroid stimulate hormone 10 . No history HIV infection negative result hepatitis B C 11 . Negative serum pregnancy test , nonlactating , use adequate contraception , female child bear potential ( intact uterus premenopausal ) 12 . Medications treatment high blood pressure and/or dyslipidemia allow regimen stable 2 month prior screen 13 . Medically stable determined history physical examination , include vital sign 14 . Electrocardiogram ( ECG ) show acute ischemia clinically significant abnormality 15 . Willing able give write informed consent 1 . Participation clinical trial use investigational agent within 30 day Study Visit 1 . 2 . History atherosclerosis include coronary artery disease , angina pectoris , myocardial infarction , cerebrovascular accident , transient ischemic attack 3 . History symptom pheochromocytoma 4 . History malignancy within 3 year except basal cell skin cancer 5 . Active infection , drug alcohol abuse , eat disorder , psychiatric disorder 6 . Concomitant medication : systemic potent topical steroid medication may affect blood glucose , e.g. , sulfonylurea , alphaglucosidase inhibitor , biguanides , meglitinides , thiazolidinediones 7 . Any condition increase risk participation trial opinion investigator</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>August 2006</verification_date>
	<keyword>diabetes</keyword>
</DOC>